Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES).
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. For maintenance of healing, 40 mg orally once daily.
* **Pathological hypersecretory conditions (ZES):** Starting dose is typically 40 mg orally or intravenously twice daily, adjusted as needed. Doses may exceed 40 mg twice daily. Maximum recommended daily oral dose is 240 mg. Maximum recommended daily IV dose is 40 mg every 8 hours.
## Pediatric Dosing
* **Erosive esophagitis (GERD-associated):**
* **1 to 5 years:** 20 mg orally once daily for up to 8 weeks.
* **6 to 16 years:** 40 mg orally once daily for up to 8 weeks.
* Dosing for pathological hypersecretory conditions in pediatric patients is not well established.
## Dose Adjustments
No dose adjustment is generally required for hepatic or renal impairment, although caution may be advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any of its components.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and flatulence. Long-term use of PPIs may be associated with an increased risk of *Clostridioides difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Pantoprazole can decrease absorption of drugs like ketoconazole, itraconazole, iron salts, and certain HIV protease inhibitors (e.g., atazanavir, nelfinavir).
* **Methotrexate:** PPIs may increase levels of methotrexate.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential interactions with drugs metabolized by this enzyme (e.g., clopidogrel, although clinical significance is debated).
## Monitoring
* Monitor for efficacy (symptom relief, healing of esophagitis).
* Monitor for adverse effects, especially with long-term use (e.g., magnesium levels, bone mineral density, *C. difficile* infection).
## Clinical Pearls
* Administer pantoprazole delayed-release tablets 30 minutes before a meal.
* For intravenous administration, reconstitute the powder for injection and further dilute. The reconstituted solution should be used within 6 hours.
* Long-term use should be reserved for patients who require ongoing therapy, and the lowest effective dose should be used.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols before making any clinical decisions.*
